| ||||||||||||||
|
|
|||||||||||||

Departments of
*Anesthesia and
Surgical Research, University Hospital Freiburg, Freiburg, Germany
Address correspondence and reprint requests to W. Karzai, MD, Department of Anesthesia, University Hospital, 07740 Jena, Germany. Address e-mail to karzai{at}anae1.med.uni-jena.de
| Abstract |
|---|
|
|
|---|
Implications: Oxygenation during one-lung ventilation depends on reflex vasoconstriction in the nonventilated lung. In vitro, desflurane inhibits this reflex dose-dependently. Our results indicate that, in vivo, this does not necessarily translate to dose-dependent decreases in oxygenation during one-lung ventilation.
| Introduction |
|---|
|
|
|---|
In vitro, increasing concentrations of all volatile anesthetics directly depress HPV in a dose-dependent manner (1,2). In vivo, however, volatile anesthetics may affect HPV not only directly, but also indirectly, by their influence on cardiac output (CO), venous oxygen saturation, and shunt fraction. It is therefore rather difficult to predict to what extent increasing concentrations of volatile anesthetics will affect oxygenation in vivo. Accordingly, it was the goal of this study to evaluate the effects of increasing concentrations of desflurane on oxygenation during OLV in vivo. In vitro, desflurane depresses HPV in a dose-dependent manner (2).
| Methods |
|---|
|
|
|---|
After DLT placement, N2O and desflurane were discontinued, and propofol was increased to 200 µg · kg-1 · min-1, a dose that produces adequate surgical anesthesia in the pig) (4,5). Subsequently, OLV (left lung) was started, and the fraction of inspired oxygen (FIO2) in air was adjusted at 0.8. Correct OLV was verified by auscultation, by capnography from each lung, or by fiberoptic bronchoscopy. After recording stable cardiorespiratory variables (mean arterial pressure, pulse rate, end-tidal carbon dioxide concentration, O2 saturation via pulse oximetry) for 10 min, propofol was discontinued, and anesthesia was continued in random order with desflurane 5% (0.5 minimum alveolar anesthetic concentration [MAC]), 10% (1 MAC), or 15% (1.5 MAC) end-tidal concentrations. Because desflurane was administered at various concentrations, particular care was taken to adjust the FIO2 at 0.8 when changing between desflurane concentrations. Respiratory and hemodynamic variables were determined at each desflurane concentration after equilibration times of at least 20 min and after end-tidal concentrations had been stable for at least 10 min.
The animals were kept in the supine position throughout the experiment. Body temperature was continuously monitored by the thermistor of the thermodilution catheter. It was maintained by placing the animals on a heating pad and by warming the IV fluids. The animals received 46 mL · kg-1 · h-1 isotonic sodium chloride solution.
Shunt fraction was calculated using the standard formula: Qs/Qt = (CcO2 - CaO2)/(CcO2 - CvO2), where CcO2 = capillary, CaO2 = arterial, and CvO2 = mixed venous oxygen content. The data were statistically analyzed by using Friedman's test using the Statistical Package for the Social Sciences® (SPSS, Chicago, IL) version 7.5. A P value of <0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
|
| Discussion |
|---|
|
|
|---|
It has been shown that the in vitro determined dose-dependent inhibition of HPV by isoflurane (6) is also operative in vivo (7). Increasing concentrations of isoflurane administered locally to the hypoxic lung were accompanied by increasing intrapulmonary shunt and decreasing systemic oxygenation (7). Therefore, a direct dose-dependent inhibition of HPV by desflurane cannot be excluded in our study but might have been counteracted by associated hemodynamic alterations.
A variety of hemodynamic alterations associated with the use of desflurane are known to modify HPV (1,8). Such modifying effects on HPV might have maintained oxygenation in vivo, even if desflurane had exhibited direct dose-dependent inhibition of HPV. CO is one factor that may obscure the direct effects of volatile anesthetics on HPV in vivo. Other studies have shown that the magnitude of HPV is flow-dependent (1,7,9). Because most volatile anesthetics decrease CO in a dose-related fashion, the net effect of increasing concentrations of volatile anesthetics on oxygenation is probably the net result of dose-dependent direct inhibiting and indirect enhancing effects on HPV. In our study, CO decreased progressively with increasing concentrations of desflurane. This may have attenuated any direct dose-dependent inhibition of desflurane on HPV.
PvO2 is another factor that may modify the HPV response in vivo. Decreases in PvO2 may enhance HPV (1,10). In our study, desflurane led to dose-dependent decreases in PvO2. Thus, decreasing PvO2 during higher concentrations of desflurane may have, in part, counteracted the increasing direct inhibitory effects of desflurane on HPV, thereby maintaining oxygenation during increasing desflurane concentrations.
In support of our assumption that CO and PvO2 might have modified the direct effects of desflurane on HPV, Qs/Qt decreased dose-dependently. In this study, any prominent direct inhibitory effect of desflurane on HPV should have resulted in an increase in Qs/Qt with increasing desflurane concentrations. Our finding that Qs/Qt actually decreased with increasing desflurane concentrations suggests that in vitro inhibition of HPV by volatile anesthetics does not necessarily translate to in vivo increases in Qs/Qt.
Why did the dose-dependent decrease in shunt volume during desflurane anesthesia not lead to a corresponding increase in oxygenation? Most likely because, at a given intrapulmonary shunt volume, decreases in the oxygen content of the shunted (venous) blood will lead to corresponding decreases in systemic oxygenation (11). Thus, during OLV, decreases in mixed venous oxygenation may, on the one hand, improve systemic oxygenation by enhancing HPV and reducing shunt volume (reducing flow to the nonventilated lung) but may, on the other hand, impair systemic oxygenation by admixture of venous blood with low oxygen saturation. In our study, there were no significant changes in PaO2 during increasing concentrations of desflurane, probably because of the modifying and interactive effects of PvO2, CO, and Qs/Qt.
In conclusion, our findings indicate that increasing concentrations of desflurane do not necessarily increase Qs/Qt or worsen oxygenation during OLV in vivo. A direct dose-dependent inhibition of HPV by desflurane [as described in vitro (2)] cannot be excluded and might have been counteracted by associated hemodynamic alterations that intensify HPV.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
E. Mirzabeigi, C. Johnson, and A. Ternian One-Lung Anesthesia Update Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2005; 9(3): 213 - 226. [Abstract] [PDF] |
||||
![]() |
K. Schwarzkopf, T. Schreiber, E. Gaser, N.-P. Preussler, L. Hueter, H. Schubert, H. Rek, and W. Karzai The Effects of Xenon or Nitrous Oxide Supplementation on Systemic Oxygenation and Pulmonary Perfusion During One-Lung Ventilation in Pigs Anesth. Analg., February 1, 2005; 100(2): 335 - 339. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Schwarzkopf, T. Schreiber, R. Bauer, H. Schubert, N.-P. Preussler, E. Gaser, U. Klein, and W. Karzai The Effects of Increasing Concentrations of Isoflurane and Desflurane on Pulmonary Perfusion and Systemic Oxygenation During One-Lung Ventilation in Pigs Anesth. Analg., December 1, 2001; 93(6): 1434 - 1438. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|